Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8,293,305 | 3,771,083 | 6,602,621 | 6,086,785 | 7,007,510 |
| Depreciation Amortization | 3,051,472 | 3,259,923 | 2,853,507 | 2,655,625 | N/A |
| Accounts receivable | -808,363 | 380,814 | -987,657 | -195,430 | N/A |
| Accounts payable and accrued liabilities | 172,750 | -228,744 | -18,659 | 611,029 | N/A |
| Other Working Capital | -2,508,167 | 327,142 | -1,064,778 | 333,963 | N/A |
| Other Operating Activity | 2,007,063 | 865,138 | 1,033,680 | -335,200 | 3,927,280 |
| Operating Cash Flow | $10,208,060 | $8,375,356 | $8,418,715 | $9,156,771 | $10,934,790 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 142,420 | 2,905,945 | 2,215,386 | 118,742 | 79,756 |
| PPE Investments | -1,745,959 | -1,704,719 | -1,599,655 | -1,233,189 | -1,414,978 |
| Net Acquisitions | -2,266,845 | -1,106,661 | -1,750,167 | -3,898,709 | -24,752 |
| Sale Of Investment | N/A | N/A | N/A | N/A | 380,903 |
| Purchase Sale Intangibles | -2,007,061 | -1,855,511 | -1,266,290 | -1,136,711 | -1,357,224 |
| Other Investing Activity | -1,711,673 | -1,665,104 | -849,585 | -5,836,934 | -1,464,482 |
| Investing Cash Flow | $-5,582,057 | $-1,570,539 | $-1,984,021 | $-10,850,090 | $-2,443,553 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,430,790 | 339,921 | -414,219 | 1,262,875 | 437,282 |
| Debt Issued | 2,609,707 | 1,373,743 | 277,390 | 1,267,823 | N/A |
| Debt Repayment | -1,846,180 | -2,063,809 | -179,122 | -1,971,619 | N/A |
| Common Stock Issued | 19,781 | 25,558 | 12,439 | 30,923 | 28,877 |
| Common Stock Repurchased | -1,815,850 | N/A | N/A | N/A | N/A |
| Dividend Paid | -3,381,147 | -3,123,188 | -2,795,043 | -4,288,333 | -5,499,025 |
| Other Financing Activity | -1,876,511 | -2,591,580 | -3,918,285 | 4,716,301 | -5,402,764 |
| Financing Cash Flow | $-4,859,410 | $-6,039,355 | $-7,016,840 | $1,017,969 | $-10,435,630 |
| Exchange Rate Effect | -25,055 | -69,007 | -123,146 | 188,009 | -39,878 |
| Beginning Cash Position | 4,487,536 | 3,652,238 | 4,260,357 | 4,723,721 | 7,235,776 |
| End Cash Position | 4,229,071 | 4,348,694 | 3,555,066 | 4,236,382 | 5,251,507 |
| Net Cash Flow | $-258,465 | $696,456 | $-705,291 | $-487,339 | $-1,984,269 |
| Free Cash Flow | |||||
| Operating Cash Flow | 10,208,060 | 8,375,356 | 8,418,715 | 9,156,771 | 10,934,790 |
| Capital Expenditure | -1,777,608 | -1,787,782 | -1,634,485 | -1,413,777 | -1,611,617 |
| Free Cash Flow | 8,430,452 | 6,587,574 | 6,784,230 | 7,742,994 | 9,323,173 |